Lausanne-based Comphya SA, a clinical-stage MedTech company innovating the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, today announced the closing of an oversubscribed Series A financing round.
Including the conversion of existing convertible loans, the round brings Comphya’s total equity raised to €8 million.
“We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with…
